ATE293695T1 - Humanes akt-3 protein - Google Patents

Humanes akt-3 protein

Info

Publication number
ATE293695T1
ATE293695T1 AT99962361T AT99962361T ATE293695T1 AT E293695 T1 ATE293695 T1 AT E293695T1 AT 99962361 T AT99962361 T AT 99962361T AT 99962361 T AT99962361 T AT 99962361T AT E293695 T1 ATE293695 T1 AT E293695T1
Authority
AT
Austria
Prior art keywords
protein
human akt
medicaments
nucleic acid
acid molecule
Prior art date
Application number
AT99962361T
Other languages
English (en)
Inventor
Stefan Leo Jozef Masure
Alan Richardson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE293695T1 publication Critical patent/ATE293695T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99962361T 1998-12-22 1999-12-17 Humanes akt-3 protein ATE293695T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828375.7A GB9828375D0 (en) 1998-12-22 1998-12-22 Human akt-3
PCT/GB1999/004311 WO2000037613A2 (en) 1998-12-22 1999-12-17 Human akt-3

Publications (1)

Publication Number Publication Date
ATE293695T1 true ATE293695T1 (de) 2005-05-15

Family

ID=10844839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962361T ATE293695T1 (de) 1998-12-22 1999-12-17 Humanes akt-3 protein

Country Status (13)

Country Link
US (1) US7071316B1 (de)
EP (1) EP1141326B1 (de)
JP (1) JP4721205B2 (de)
AT (1) ATE293695T1 (de)
AU (1) AU774718B2 (de)
CA (1) CA2355834C (de)
DE (1) DE69924877T2 (de)
DK (1) DK1141326T3 (de)
ES (1) ES2242441T3 (de)
GB (1) GB9828375D0 (de)
IL (2) IL143862A0 (de)
NZ (1) NZ512933A (de)
WO (1) WO2000037613A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310515T3 (es) * 1999-03-19 2009-01-16 Aventis Pharmaceuticals Inc. Acidos nucleicos akt-3, polipeptidos y usos de los mismos.
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
US6187586B1 (en) * 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
DE10011530A1 (de) * 2000-03-13 2001-09-27 Robert Elez Hochwirksame Antisense-Oligodesoxynucleotide gegen Polio-like Kinasel
CN1331317A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人丝氨酸/苏氨酸蛋白激酶11.22和编码这种多肽的多核苷酸
EP1195604A1 (de) * 2000-09-29 2002-04-10 Warner-Lambert Company Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Lipidkinasen
WO2006022718A1 (en) * 2004-08-13 2006-03-02 Novartis Vaccines And Diagnostics Inc. Akt3 compositions and methods of use
EP2304439A4 (de) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anti-phospho-akt-antikörper
AU2020232692A1 (en) * 2019-03-04 2021-09-30 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the AKT pathway

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT862622E (pt) * 1995-11-16 2005-01-31 Novartis Ag Metodo de rastreio para compostos que interagem com proteina cinase rac

Also Published As

Publication number Publication date
IL143862A (en) 2008-11-26
WO2000037613A2 (en) 2000-06-29
NZ512933A (en) 2003-11-28
ES2242441T3 (es) 2005-11-01
WO2000037613A3 (en) 2000-11-16
JP4721205B2 (ja) 2011-07-13
DK1141326T3 (da) 2005-08-22
CA2355834A1 (en) 2000-06-29
US7071316B1 (en) 2006-07-04
IL143862A0 (en) 2002-04-21
EP1141326A2 (de) 2001-10-10
DE69924877D1 (en) 2005-05-25
EP1141326B1 (de) 2005-04-20
CA2355834C (en) 2010-02-23
AU1873200A (en) 2000-07-12
AU774718B2 (en) 2004-07-08
JP2002535964A (ja) 2002-10-29
DE69924877T2 (de) 2006-05-11
GB9828375D0 (en) 1999-02-17

Similar Documents

Publication Publication Date Title
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
GR20010300006T1 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
AU1922101A (en) Human fgf-21 gene and gene expression products
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
WO2002061076A1 (fr) Proteine associee a l'adiponectine
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
DK1141326T3 (da) Human Akt-3
ATE297464T1 (de) Pharmazeutische zusammensetzungen zur therapie der herzinsuffizienz
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
AU3172095A (en) Coccidiosis poultry vaccine
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
BG101846A (bg) Варианти на човешка дезоксирибонуклеаза i
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
JP2002348254A5 (de)
DE50000562D1 (de) Mittel zur behandlung von pigmentierungsstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties